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Background: The aim of this study was to determine the early mortality and major complications of acute
complicated type B aortic dissection (ACBD) after thoracic endovascular aortic repair (TEVAR).
Methods: Twenty-six consecutive patients with ACBD who underwent TEVAR were included. Clinical indications
before TEVAR and in-hospital mortality and major complications after TEVAR were analyzed and compared with
similar reports.
Results: TEVAR was technically successful in all cases. In-hospital mortality occurred in four patients (15%), and
major complications occurred in an additional four patients (15%). Three of the four (75%) of the deaths were
associated with malperfusion and ischemia reperfusion injury (IRI), and 3/4 (75%) of the major complications were
caused by respiratory failure (RF).
Conclusions: In-hospital mortality associated strongly with severe end-organ malperfusion and IRI, while major
complications associated with RF, during TEVAR. Our results indicate that malperfusion, IRI and respiratory failure
during TEVAR should be carefully monitored and aggressively treated.Background
Thoracic endovascular aortic repair (TEVAR) is the
promising treatment for acute complicated type B aortic
dissection (ACBD) [1-4]. During the acute phase of the
dissection, TEVAR can obviate impending aortic rupture
and relieve dynamic malperfusion [5,6]. A delayed bene-
fit is potentiation of thrombosis within the thoracic false
lumen, thereby mitigating the risk of aneurysmal dilata-
tion and subsequent aortic rupture [7-9]. TEVAR is su-
perior to conventional surgical repair, which is more
invasive and has more potential complications.
Despite the short-term benefits (low morbidity and
mortality) of TEVAR for the repair of ACBD [1,4], an
increasing number of studies report early mortality and
major complications after TEVAR [7,10-12]. Major* Correspondence: pla301dml@vip.sina.com
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reproduction in any medium, provided the orcomplications of TEVAR include permanent renal fail-
ure, stroke, paraplegia, and respiratory failure (RF). An
analysis of early mortality and major complications, with
the exclusion of procedure-related factors, would pro-
vide a better understanding of the impact of TEVAR on
ACBD outcomes and provide insight in the clinical deci-
sions of when to use TEVAR and when to add adjuvant
therapy to the TEVAR procedure. Therefore, this study
focused on ACBD patients to identify indicators that
could predict in-hospital mortality or major complica-
tions during TEVAR.Methods
Patients
From March 2004 to October 2010, 26 consecutive
patients with ACBD underwent TEVAR in our depart-
ment. TEVAR was performed less than 14 days after the
onset of symptoms in all cases. The clinical characteristicstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 TEVAR procedure characteristics
Variable Number (%)
Time interval between symptom onset and
procedure
(d; Mean ± SD (Range)) 7.8 ± 4.4 (1–14)
Stent graft oversizing aorta diameter of landing
zone
10% 20 (76.9)
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confirmed Stanford type B dissection by computed tomog-
raphy (CT) angiography. ACBD was diagnosed according
to the signs and symptoms, including severe end-organ
malperfusion, persistent pain, acute aortic failure, refrac-
tory hypertension and encephalopathy.
Techniques
Before the endovascular procedure, CT angiography was
used to measure the distance and diameter of the landing
zone, which is the normal part of the aorta used to attach
the stent graft during the TEVAR procedure. During the
procedure, the landing zone diameter was determined by
digital subtraction angiography. The diameter of the
selected stent graft was 10-20% larger than the landing zone
diameter. All procedures were performed in an angiography
unit (INNOVA 3100, GE Medical Systems, Milwaukee,
WI). Local anesthesia was used in two cases due to pre-
existing cardiac and respiratory dysfunction, while general
anesthesia was performed in the remaining 24 cases.
All stent grafts were deployed with the common femoral
artery approach via unilateral femoral access. It was not
necessary to use conduits for any of the cases. The tech-
nical details of TEVAR have been described by Nienaber
[13]. Once the true lumen wire access through the left
brachial artery was confirmed in the ascending aorta, arch
angiography was performed. If imaging indicated the need
for left subclavian artery coverage, selective vertebral angi-
ography was performed to evaluate the adequacy of collat-
eral vertebral artery flow and to confirm the absence of
internal mammary grafts.
Patients were systemically heparinized with a dosage
of 100 IU/kg by intravenous bolus injection. The deliveryTable 1 Baseline characteristics and CT findings
Variable Number (%)
Sex (Male/ Female) 23/ 3
Age (y; Mean ± SD (Range)) 52.8 ± 13.1 (31–72)
Descending aorta dimension (mm; Mean ± SD
(Range))
29.0 ± 2.7 (23–36)
Patients in distance from LSCA to primary tear
< 1.5 cm 13 (50.0)
> 1.5 cm 13 (50.0)
True lumen appearance
Patent 20 (76.9)
Severe Stenosis (location) # 2 (7.7)
Thoracic aorta 1 (3.8)
Common iliac 1 (3.8)
Occlusion 4 (15.4)
Abdominal aorta below the renal artery 1 (3.8)
Common iliac 3 (11.5)
LSCA- left subclavian artery; # Diameter decreased more than 80%.system dilator–sheath was advanced into the aortic true
lumen, and the stent graft was advanced to completely
cover the primary intimal tear. The systolic blood pres-
sure was lowered to less than 100 mmHg, and the heart
rate was lowered to below 90 beats/min. In order to
exclude false lumen flow, the stent graft was delivered
under fluoroscopic guidance to cover the primary in-
timal tear. Ballooning of the stent graft was performed
only if a large type Ia proximal endoleak was documen-
ted, and ballooning occurred only at the proximal land-
ing zone. When needed, a second stent graft was placed.
Angiography confirmed the absence of endoleaks and
determined the perfusion status of the previously ische-
mic arterial beds. Technical success was determined by
exclusion of proximal primary entry flap on the comple-
tion angiogram. The details of TEVAR procedures are
listed in Table 2.
ACBD patients with severe end-organ malperfusion
who underwent TEVAR were administered prophylactic
hemodialysis. In the case of ACBD with severe malperfu-
sion, the important organs affected were the kidney, the
intestine and the lower extremities. Severe end-organ
malperfusion was empirically defined as the appearance15% 4 (15.4)
20% 2 (7.7)
Size of the stent graft # (mm; mean ± SD (Range))
Proximal diameter 33.7 ± 3.6 (28–40)
Distal diameter 33.4 ± 3.8 (28–40)
Graft length 127.6 ± 29.2 (60–
162)
Coverage of branch artery
LSCA coverage 9 (34.6)
LSCA dominant 2 (7.7)
Aberrant RSCA coverage 1 (3.8)
LCCA coverage 2 (7.7)
Partial LCCA coverage 1 (3.8)
Length of aorta covered (cm; mean ± SD (Range)) 13.5 ± 2.9 (6–18)
Operation time (h; mean ± SD (Range)) 2.2 ± 1.1 (1–6.4)
Contrast volume (ml; mean ± SD (Range)) 190 ± 61.2 (100–
350)
LSCA- left subclavian artery; RSCA- right subclavian artery; LCCA- left common
carotid artery.
# Two stent grafts were implanted in one patient.
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chemia [14], intestine malperfusion related hematoche-
zia or hematemesis, blood creatinine level ≥ 500 μmol/L,
or blood creatine kinase ≥ 10000 IU/L. According to em-
pirical indicators of the severe end-organ malperfusion,
patients with more than two indicators were adminis-
tered prophylactic hemodialysis after TEVAR.
Data collection and statistical analysis
Data collected included age, survival status, graft compo-
nents utilized, access arteries, subclavian artery coverage,
length of in-hospital stay, major/minor in-hospital compli-
cations, and status of the false lumen immediately after
procedure. Major complications were defined as events
that were life threatening or would prompt major thera-
peutic consequences (e.g., access complications requiring
surgical revision, re-interventional treatment or requiring
dialysis). Minor complications were defined as that no fur-
ther treatment was required (e.g., transient renal failure
not requiring dialysis or transient spinal cord ischemia).
This was a retrospective, non-comparative analysis. All
statistical data were descriptive on an intent-to-treat
basis. Discrete variables were presented as percentages,
while continuous variables were presented as counts and
are presented as mean ± SD. The ethical approval for
this study was provided by the Ethical Committee of the
Chinese PLA General Hospital.
Results
Procedural data
Symptomatic indications for intervention included per-
sistent pain (23 patients), malperfusion (10 patients),
aortic failure (8 patients), and refractory hypertension
(5 patients). Multiple indicators were present in 16
patients (Table 3).Table 3 Indicators for TEVAR
Indications n
Malperfusion 10 (38.5%)
Lower extremity ischemia 4
Paraplegia 2
Renal artery malperfusion 7
SMA malperfusion 6
Refractory hypertension/ encephalopathy 5/2 (19.2%)
Persistent Pain 23 (88.5%)
Chest pain 14
Abdominal pain 16
Aortic failure 8 (30.8%)
Acute true lumen collapse 3
Severe pleural effusion 6
Twelve patients had two indications and four patients had three indications.
SMA: superior mesenteric artery.Six types of stent graft systems were used, including
Talent (Medtronic Inc, Minneapolis, MN; n = 11), Valiant
(Medtronic Inc, Minneapolis, MN; n = 8), Zenith (COOK,
Inc, Bloomington, IN; n = 1), Endofit (Endologix Inc,
Irvine, CA; n = 3), Hercules (Microport, Shanghai, China;
n = 4) and Ankura (Lifetech, Shenzhen, China; n = 2). One
stent graft was implanted in 25 patients, and two stent
grafts were implanted in one patient to cover multiple
tears on the distal descending aorta. The coverage dis-
tance between the left common carotiod artery (LCCA)
and the primary tear was less than 15 mm in two patients.
Technical success was achieved in all patients. Delivery
system via the femoral approach was successful in all 26
patients, requiring unilateral incision in 24 cases, bilat-
eral femoral incisions in one case, and unilateral incision
with contralateral percutaneous access in one case. Im-
mediate postoperative angiography showed no re-entry
site at the distal end of the false lumen of six patients
with ACBD. The blood supply of visceral arteries via the
false lumen was found in the remaining 20 cases.
Twenty patients (77%) required intensive care unit
(ICU) monitoring and continuous intravenous infusion
of antihypertensive agents. The average length of hos-
pital stay was 13.8 ± 9.9 days (range, 1 to 38 days).
Based on the angiographic findings and patient symp-
toms, all patients with malperfusion had immediate
resolution of the malperfusion deficit after the proced-
ure. Endoleaks were detected in six patients using pro-
cedural angiography; five with Type Ia endoleak, in
which left subclavian artery was covered in three cases,
and one with a Type II endoleak. All patients with endo-
leaks were untreated in the procedure.
In-hospital deaths and major complications
Clinical data for the patients who died or had major
complications are summarized in Table 4. Four patients
died and four patients experienced major complications
following TEVAR. In these patients, the average length
of stay in the ICU was 12.9 ± 9.8 days (range, 0 to
29 days) after the procedure. Three deaths were attribu-
ted to pre-existing organ malperfusion and ischemia
reperfusion injury (IRI), and one was attributed to RF,
respiratory infection, and renal failure (Table 4). An in-
dependent Clinical Events Committee adjudicated that
all deaths were not related to the TEVAR procedure
itself.
In six patients with SMA malperfusion and a bloody
stool, two died and one had a major complication after
the procedure. Of the other three patients, all survived
without any symptoms of intestinal ischemia. In four
patients with lower extremity malperfusion, two patients
had Type III ischemic mottling who died after the
procedure. One patient had no pulse, pallor, and
paresthesia, but he survived once the lower extremity
Table 4 Patient outcomes
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RA, renal artery; SMA, superior mesenteric artery; CIA, common iliac artery; MOF, multiple organ failure; ARDS, adult respiratory distress syndrome; EIA, external
iliac artery; IRI, ischemic reperfusion injury. aThe classification of low extremity ischemia was from reference 14.
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malperfusion before the procedure, only one patient had
renal dysfunction after the procedure. Three patients
with three indicators of severe end-organ malperfusion
died even though hemodialysis was administered after
TEVAR (Table 4).
In four patients with major complications after the
procedure, three had RF and respiratory infection. An-
other patient had pre-existing organ malperfusion and
IRI. In four patients with RF after the procedure, the
duration of tracheal intubation was 20 ± 7.8 days (range,
11 to 29). Only one patient had severe pleural effusion
before the procedure. In six patients with severe pleural
effusion after the procedure, five accepted tracheal
extubation immediately after the procedure, while onepatient with tracheal intubation for 16 days had RF and
respiratory infection.
Two patients had minor complications. One patient
had a headache that resolved five days after the proced-
ure. The other patient had right low extremity malperfu-
sion and transient renal failure, but recovered one week
after the procedure without the need for dialysis. In 23
patients with persistent chest or abdominal pain before
the procedure, three died from malperfusion and IRI,
while three of the survivors had persistent chest and
abdominal pain that was unrelieved. In five patients with
refractory hypertension before the procedure, one died.
Of the remaining four survivors, three patients had
refractory hypertension that resolved on its own. Except
for one pre-procedural paraplegia patient, none of the
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treatment at the time of hospital discharge.
Follow-up data
All 22 in-hospital live patients were followed up from 1
to 49 months (average, 6.8 ± 7.3 months). The type Ia
endoleak in 4 patients spontaneous resolved at one
month. The endoleaks in another 2 patients (1 with type
Ia and 1 with type II) were observed at three month.
Two deaths occurred at 2 and 3 months and the reasons
were unclear. One late deaths was as the result of pul-
monary carcinoma at 24 months.
Discussion
Both dissection rupture or imminent rupture and mal-
perfusion are indicators for emergency TEVAR in a pa-
tient with ACBD [15]. In fact, imminent rupture is
difficult to determine clinically in a patient with ACBD,
and dissection rupture is more rare than malperfusion
[9,15,16]. The most significant findings of this study
were that in-hospital mortality associated with severe
end-organ malperfusion IRI and major complications
associated with RF during TEVAR.
There were 10 patients (38.5%) with malperfusion in
our group; however, no patients showed evidence of dis-
section rupture or imminent rupture. In previous single-
center studies, malperfusion was a common indicator
among patients (Table 5). Before our study, the poor
prognosis of malperfusion had not been systematically
analyzed. Compared with other indicators, including
refractory hypertension, persistent pain and aorta failure,
malperfusion is a more urgent indicator for emergency
TEVAR. This is due to the fact that end-organ malperfu-
sion and subsequent life-threatening organ failure are
imminent results. In addition, the severity of ACBD
malperfusion and IRI appear to be more closely related
to early mortality following TEVAR than the other
complications.
After TEVAR, the malperfused end-organ artery may
open causing early IRI. Irreversible malperfusion and early
IRI can increase the systemic absorption of metabolic tox-
ins, which may become a direct cause of multiple organTable 5 Malperfusion proportion in ACBD patients
Study Malperfusion (n) ACBD (n) Proportion
Szeto [4] 17 35 48.6
Feezor [6] 11 33 33.3
Conrad [7] 17 33 51.5
Parsa [12] 11 22 50
Pearce [15] 8 15 53.3
Khoynezhad [16] 15 28 53.6
Botsios [17] 6 32 18.8
ACBD = acute complicated type B aortic dissection.failure and death after TEVAR. If end-organ malperfusion
is more serious, then the IRI will be more serious after
TEVAR and early mortality will consequently be higher.
In-hospital mortality following TEVAR occurred in three
of the 10 patients with malperfusion and accounted for
three of four (75%) in-hospital deaths. In similar single-
center studies, Pearce [16] and Szeto [4] reported a higher
proportion of malperfusion (Table 5), but no malperfusion-
related mortality. In other similar two single-center studies,
Khoynezhad [17] and Feezor [6] reported a higher
proportion of malperfusion (Table 5) and significant
malperfusion-related mortality rates (7% and 13.3%,
respectively). In our study, the three malperfusion-related
deaths occurred in patients who had severe malperfusion
and IRI of one or two end-organs. In studies by Pearce
[16], Szetodl [4], Khoynezhad [17] and Feezor [6], informa-
tion regarding the degree of end-organ ischemia was not
included. Classification of the degree of end-organ malper-
fusion would help predict the mortality rate after TEVAR.
In the process of TEVAR, many surgeons use surgical
or interventional fenestration [18,19] or branch vessel
stenting [6] to handle persistent malperfusion. There are
few reports about the process of IRI in malperfusion
with an open end-organ artery.
In our study, three of five ACBD patients with severe
malperfusion suffered IRI, multiple organ failure, and
in-hospital death even though they received prophylactic
hemodialysis post-TEVAR. We found that the clearance
of metabolic toxins was poor in improving survival of
severe malperfusion ACBDs. For these patients, removal
of severe malperfusion end-organs may be acquired
more beneficial than re-opening the end-organ artery.
Currently, more published reports of ACBD have been
concerned how to reopen malperfusion end-organ arter-
ies in TEVAR [3,6,15,20-24]. Fenestration and stenting
have been used frequently, and prosthetic bypass has
been used in visceral malperfusion.
There are few reports detailing when malperfusion
persists to result in end-organ ischemia, nor are there
any reports regarding the assessment of the degree of
end-organ malperfusion, IRI severity and reversibility of
malperfusion end-organ function in TEVAR therapy. In
our study, the cause of three ACBD patient deaths were
malperfusion and IRI, who had more than two indicators
of severe end-organ malperfusion (Table 4). On the
other hand, two malperfusion ACBD patients who sur-
vived had only two indicators (Table 4). The other five
malperufsion ACBD patients who survived had no indi-
cators of severe end-organ malperfusion. Re-opening the
malperfusion artery is not a unique option. We propose
that nonreversible end-organ malperfusion is an indica-
tion for primary surgical removal of end-organs (e.g., ex-
tremity amputation, intestine resection). Some centers
have reported a little experience of organ resection, but
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postoperative prognosis is still unknown [9,21]. Our
study suggests that a number of indicators of severe
end-organs malperfusion could become the basis of mal-
perfusion organ removal or malperfusion organ artery
re-opening.
RF occurred postoperatively in four patients, including
one who died. The cause of postoperative RF was not
clear because these patients had no pulmonary disease
or severe malperfusion, with the exception of one patient
who had preoperative pleural effusion and obesity. In
regards to the possible causes of respiratory failure, it
has been reported that ischemia and reperfusion of in-
testine, renal, and lower extremity may cause distant
pulmonary injury. Feezor et a.l [6] reported that 11 of 33
ACBD patients who underwent emergency TEVAR suf-
fered RF without any apparent underlying cause. Add-
itionally, Sachs [25] showed respiratory complications
accounted for 4.3% of type B dissections after TEVAR.
Kurabayashi [26] demonstrated that the only independ-
ent predictor of oxygenation impairment was acute aor-
tic dissection (odds ratio, 1.323; 95% confidence interval,
1.035-1.691, P = 0.026). This study proposed that RF in
acute aortic dissection closely correlated with aortic in-
jury, possibly mediated by the magnitude of the systemic
inflammatory reaction to the aortic injury. Eggebrecht
[27] quantified inflammatory markers in patients who
underwent TEVAR and found that post-procedural
inflammatory responses were more pronounced and cor-
related with mortality. Furthermore, it was shown that
post-operative RF closely correlated with a systemic
inflammatory response syndrome that attacked the
lungs. Respiratory infection readily occurred in patients
with RF who underwent long-term tracheal intubation.
In our study, the four patients with postoperative RF
remained intubated for at least 8 days, and they all
developed respiratory infection. Respiratory infection
may aggravate RF, which was confirmed in patients with
thoracic aortic aneurysm who underwent TEVAR [28].
However, it remains unclear whether the systemic in-
flammatory response syndrome and respiratory infection
induce a malignant cycle that further induces RF. Fortu-
nately, three of the four patients with postoperative RF
recovered. Therefore, the etiology of RF after TEVAR
and how to prevent it warrants more study.Conclusions
This study shows that malperfusion is the more com-
mon indicator for ACBD patients to receive emergency
TEVAR. The in-hospital mortality of malperfusion
ACBD after TEVAR is closely related to malperfusion
and IRI. RF is a common major complication of ACBD
after TEVAR and may cause respiratory infection. Thecorrelation between RF and systemic inflammation re-
main to be further understood.
The most effective prevention and treatment of IRI is
to restore blood flow as early as possible. Procedures to
improve the perfusion to ischemic end-organs should
not be delayed only because of fear of reperfusion injury,
unless irreversible ischemia has been proved.
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